{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:00:45Z","timestamp":1787029245459,"version":"build-2736575974"},"reference-count":62,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Retinopathy of prematurity (ROP) is a severe condition primarily affecting premature infants with a gestational age (GA) of 30 weeks or less and a birth weight (BW) of 1500 g or less. The objective of this review is to examine the risk factors, pathogenesis, and current treatments for ROP, such as cryotherapy, laser photocoagulation, and anti-VEGF therapy, while exploring the limitations of these approaches. Additionally, this review evaluates emerging nanotherapeutic strategies to address these challenges, aiming to improve ROP management. Methods: A comprehensive literature review was conducted to gather data on the pathogenesis, traditional treatment methods, and novel nanotherapeutic approaches for ROP. This included assessing the efficacy and safety profiles of cryotherapy, laser treatment, anti-VEGF therapy, and nanotherapies currently under investigation. Results: Traditional treatments, while effective in reducing disease progression, exhibit limitations, including long-term complications, tissue damage, and systemic side effects. Nanotherapeutic approaches, on the other hand, have shown potential in offering targeted drug delivery with reduced systemic toxicity, improved ocular drug penetration, and sustained release, which could decrease the frequency of treatments and enhance therapeutic outcomes. Conclusions: Nanotherapies represent a promising advancement in ROP treatment, offering safer and more effective management strategies. These innovations could address the limitations of traditional therapies, reducing complications and improving outcomes for premature infants affected by ROP. Further research is needed to confirm their efficacy and safety in clinical practice.<\/jats:p>","DOI":"10.3390\/ph17101377","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T07:58:32Z","timestamp":1729065512000},"page":"1377","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Innovative Use of Nanomaterials in Treating Retinopathy of Prematurity"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1662-6900","authenticated-orcid":false,"given":"Kevin Y.","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Surgery, Division of Ophthalmology, University of Sherbrooke, Sherbrooke, QC J1G 2E8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingao C.","family":"Wang","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3T 1J4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maude","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Ophthalmology, University of Sherbrooke, Sherbrooke, QC J1G 2E8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5594-359X","authenticated-orcid":false,"given":"Simon D.","family":"Tran","sequence":"additional","affiliation":[{"name":"Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, QC H3A 1G1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1084-2756(03)00119-2","article-title":"Pathogenesis of Retinopathy of Prematurity","volume":"8","author":"Smith","year":"2003","journal-title":"Semin. Neonatol."},{"key":"ref_2","unstructured":"Brown, A.C., and Nwanyanwu, K. (2024). Retinopathy of Prematurity. StatPearls, StatPearls Publishing."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group (2001). Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: Ophthalmological Outcomes at 10 Years. Arch. Ophthalmol., 119, 1110\u20131118.","DOI":"10.1001\/archopht.119.8.1110"},{"key":"ref_4","first-page":"233","article-title":"Final Results of the Early Treatment for Retinopathy of Prematurity (ETROP) Randomized Trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity","volume":"364","author":"Kennedy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Wu, K.Y., Joly-Chevrier, M., Akbar, D., and Tran, S.D. (2023). Overcoming Treatment Challenges in Posterior Segment Diseases with Biodegradable Nano-Based Drug Delivery Systems. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15041094"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.survophthal.2018.04.002","article-title":"Retinopathy of Prematurity: A Review of Risk Factors and Their Clinical Significance","volume":"63","author":"Kim","year":"2018","journal-title":"Surv. Ophthalmol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"The International Committee for the Classification of Retinopathy of Prematurity (2005). The International Classification of Retinopathy of Prematurity Revisited. Arch. Ophthalmol., 123, 991\u2013999.","DOI":"10.1001\/archopht.123.7.991"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.oret.2019.12.015","article-title":"Late-Onset Retinal Findings and Complications in Untreated Retinopathy of Prematurity","volume":"4","author":"Hamad","year":"2020","journal-title":"Ophthalmol. Retin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/bjo.2003.022962","article-title":"Late Onset Vitreoretinal Complications of Regressed Retinopathy of Prematurity","volume":"88","author":"Tufail","year":"2004","journal-title":"Br. J. Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e20183061","DOI":"10.1542\/peds.2018-3061","article-title":"Screening Examination of Premature Infants for Retinopathy of Prematurity","volume":"142","author":"Fierson","year":"2018","journal-title":"Pediatrics"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists, Fierson, W.M., Saunders, R.A., Good, W., Palmer, E.A., Phelps, D., and Reynolds, J. (2013). Screening Examination of Premature Infants for Retinopathy of Prematurity. Pediatrics, 131, 189\u2013195.","DOI":"10.1542\/peds.2012-2996"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group and the National Eye Institute Author (1988). Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: Preliminary Results. Arch. Ophthalmol., 106, 471\u2013479.","DOI":"10.1001\/archopht.1988.01060130517027"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0161-6420(01)01015-6","article-title":"A Comparison of Laser Photocoagulation with Cryotherapy for Threshold Retinopathy of Prematurity at 10 Years: Part 2. Refractive outcome","volume":"109","author":"Connolly","year":"2002","journal-title":"Ophthalmology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0161-6420(01)01017-X","article-title":"A Comparison of Laser Photocoagulation with Cryotherapy for Threshold Retinopathy of Prematurity at 10 Years: Part 1. Visual function and structural outcome","volume":"109","author":"Ng","year":"2002","journal-title":"Ophthalmology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.earlhumdev.2007.11.007","article-title":"Treatment of Retinopathy of Prematurity","volume":"84","author":"Clark","year":"2008","journal-title":"Early Hum. Dev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0161-6420(91)32247-4","article-title":"Laser Photocoagulation for Stage 3+ Retinopathy of Prematurity","volume":"98","author":"McNamara","year":"1991","journal-title":"Ophthalmology"},{"key":"ref_18","first-page":"615","article-title":"Iris Atrophy, Cataracts, and Hypotony Following Peripheral Ablation for Threshold Retinopathy of Prematurity","volume":"119","author":"Kaiser","year":"2001","journal-title":"Arch. Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1097\/IAE.0b013e318159ec39","article-title":"Anterior Segment Ischemia Following Laser Therapy for Threshold Retinopathy of Prematurity","volume":"28","author":"Gaitan","year":"2008","journal-title":"Retina"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0002-9394(99)00475-4","article-title":"Cataract and Phthisis Bulbi after Laser Photoablation for Threshold Retinopathy of Prematurity","volume":"129","author":"Lambert","year":"2000","journal-title":"Am. J. Ophthalmol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ajjarapu, A., and Dumitrescu, A. (2023). Delayed Anterior Segment Complications after the Treatment of Retinopathy of Prematurity with Laser Photocoagulation. Front. Ophthalmol., 3.","DOI":"10.3389\/fopht.2023.1270591"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1002\/jcb.30344","article-title":"Molecular Mechanism of VEGF and Its Role in Pathological Angiogenesis","volume":"123","author":"Ahmad","year":"2022","journal-title":"J. Cell. Biochem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"F327","DOI":"10.1136\/archdischild-2012-302365","article-title":"Serious Adverse Events and Visual Outcomes of Rescue Therapy Using Adjunct Bevacizumab to Laser and Surgery for Retinopathy of Prematurity. The Indian Twin Cities Retinopathy of Prematurity Screening Database Report Number 5","volume":"98","author":"Jalali","year":"2013","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1097\/IAE.0000000000001685","article-title":"Progressive Retinal Detachment in Infants with Retinopathy of Prematurity Treated with Intravitreal Bevacizumab or Ranibizumab","volume":"38","author":"Yonekawa","year":"2018","journal-title":"Retina"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1167\/iovs.13-11625","article-title":"Anti-VEGF Antibody Leads to Later Atypical Intravitreous Neovascularization and Activation of Angiogenic Pathways in a Rat Model of Retinopathy of Prematurity","volume":"54","author":"McCloskey","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.exer.2018.01.020","article-title":"The Effect of a Single Anti-Vascular Endothelial Growth Factor Injection on Neonatal Growth and Organ Development: In-Vivo Study","volume":"169","author":"Khalili","year":"2018","journal-title":"Exp. Eye Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ydbio.2019.11.016","article-title":"Neuron-Derived VEGF Contributes to Cortical and Hippocampal Development Independently of VEGFR1\/2-Mediated Neurotrophism","volume":"459","author":"Okabe","year":"2020","journal-title":"Dev. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/pr.2018.41","article-title":"Vascular Endothelial Growth Factor Accelerates Compensatory Lung Growth by Increasing the Alveolar Units","volume":"83","author":"Dao","year":"2018","journal-title":"Pediatr. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e20183537","DOI":"10.1542\/peds.2018-3537","article-title":"Neurodevelopmental Outcomes of Preterm Infants with Retinopathy of Prematurity by Treatment","volume":"144","author":"Natarajan","year":"2019","journal-title":"Pediatrics"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Pinel, B., Porras-Alcal\u00e1, C., Ortega-Rodr\u00edguez, A., Sarabia, F., Prados, J., Melguizo, C., and L\u00f3pez-Romero, J.M. (2019). Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment. Nanomaterials, 9.","DOI":"10.3390\/nano9040638"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid Nanoparticles\u2500From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"105084","DOI":"10.1016\/j.chemphyslip.2021.105084","article-title":"Liposome Surface Modification by Phospholipid Chemical Reactions","volume":"237","author":"Lima","year":"2021","journal-title":"Chem. Phys. Lipids"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"eabo6638","DOI":"10.1126\/sciadv.abo6638","article-title":"A Single Intravenous Injection of Cyclosporin A\u2014Loaded Lipid Nanocapsules Prevents Retinopathy of Prematurity","volume":"8","author":"Bohley","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1126\/science.1523409","article-title":"Oxidized Redox State of Glutathione in the Endoplasmic Reticulum","volume":"257","author":"Hwang","year":"1992","journal-title":"Science"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1007\/s00417-020-04797-3","article-title":"Inhibition of Retinal Neovascularization by VEGF siRNA Delivered via Bioreducible Lipid-like Nanoparticles","volume":"258","author":"Wang","year":"2020","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"115136","DOI":"10.1016\/j.addr.2023.115136","article-title":"Lipid Nanoparticles for Targeted Delivery of Anticancer Therapeutics: Recent Advances in Development of siRNA and Lipoprotein-Mimicking Nanocarriers","volume":"203","author":"Yaghmur","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1158\/1078-0432.CCR-04-2482","article-title":"Antiangiogenic Properties of Gold Nanoparticles","volume":"11","author":"Mukherjee","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"505101","DOI":"10.1088\/0957-4484\/20\/50\/505101","article-title":"Intravenously Administered Gold Nanoparticles Pass through the Blood\u2013Retinal Barrier Depending on the Particle Size, and Induce No Retinal Toxicity","volume":"20","author":"Kim","year":"2009","journal-title":"Nanotechnology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.biomaterials.2010.11.030","article-title":"The Inhibition of Retinal Neovascularization by Gold Nanoparticles via Suppression of VEGFR-2 Activation","volume":"32","author":"Kim","year":"2011","journal-title":"Biomaterials"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.nano.2017.03.016","article-title":"Intraocular Application of Gold Nanodisks Optically Tuned for Optical Coherence Tomography: Inhibitory Effect on Retinal Neovascularization without Unbearable Toxicity","volume":"13","author":"Song","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"S\u00f6derstjerna, E., Bauer, P., Cedervall, T., Abdshill, H., Johansson, F., and Johansson, U.E. (2014). Silver and Gold Nanoparticles Exposure to In Vitro Cultured Retina\u2014Studies on Nanoparticle Internalization, Apoptosis, Oxidative Stress, Glial- and Microglial Activity. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0105359"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Zieli\u0144ska, A., Carreir\u00f3, F., Oliveira, A.M., Neves, A., Pires, B., Venkatesh, D.N., Durazzo, A., Lucarini, M., Eder, P., and Silva, A.M. (2020). Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology. Molecules, 25.","DOI":"10.3390\/molecules25163731"},{"key":"ref_44","first-page":"4160","article-title":"Nanoparticle-Medicated Delivery of Hydrophobic Compounds to Retinal Microvascular Endothelial Cells","volume":"56","author":"Zhang","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.biopha.2018.08.092","article-title":"Effect of Nanoencapsulation Using Poly (Lactide-Co-Glycolide) (PLGA) on Anti-Angiogenic Activity of Bevacizumab for Ocular Angiogenesis Therapy","volume":"107","author":"Zhang","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.exer.2011.10.013","article-title":"Expression of Pro- and Anti-Angiogenic Isoforms of VEGF in the Mouse Model of Oxygen-Induced Retinopathy","volume":"93","author":"Zhao","year":"2011","journal-title":"Exp. Eye Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/02713683.2018.1542736","article-title":"Intravitreal Delivery of VEGF-A165-Loaded PLGA Microparticles Reduces Retinal Vaso-Obliteration in an In Vivo Mouse Model of Retinopathy of Prematurity","volume":"44","author":"Wang","year":"2019","journal-title":"Curr. Eye Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"717","DOI":"10.4103\/ijo.IJO_496_19","article-title":"The Changing Scenario of Retinopathy of Prematurity in Middle and Low Income Countries: Unique Solutions for Unique Problems","volume":"67","author":"Vinekar","year":"2019","journal-title":"Indian. J. Ophthalmol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0031-3955(05)70245-5","article-title":"Topical therapies and medications in the pediatric patient","volume":"47","author":"Metry","year":"2000","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bcp.12305","article-title":"Clinical Trials in Children","volume":"79","author":"Joseph","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.drudis.2022.05.024","article-title":"Targeted Drug Delivery to the Retinal Pigment Epithelium: Untapped Therapeutic Potential for Retinal Diseases","volume":"27","author":"Bohley","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/02713683.2019.1565890","article-title":"Morphology and Composition of the Inner Limiting Membrane: Species-Specific Variations and Relevance toward Drug Delivery Research","volume":"44","author":"Peynshaert","year":"2019","journal-title":"Curr. Eye Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense Oligonucleotides: The next Frontier for Treatment of Neurological Disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jconrel.2011.11.022","article-title":"Ocular Antisense Oligonucleotide Delivery by Cationic Nanoemulsion for Improved Treatment of Ocular Neovascularization: An in-Vivo Study in Rats and Mice","volume":"160","author":"Hagigit","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jconrel.2022.08.006","article-title":"Immunomodulation of MiRNA-223-Based Nanoplatform for Targeted Therapy in Retinopathy of Prematurity","volume":"350","author":"Huang","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1152\/physrev.00021.2004","article-title":"The Retinal Pigment Epithelium in Visual Function","volume":"85","author":"Strauss","year":"2005","journal-title":"Physiol. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1161\/ATVBAHA.114.304627","article-title":"Nanoparticle-Mediated Expression of a Wnt Pathway Inhibitor Ameliorates Ocular Neovascularization","volume":"35","author":"Wang","year":"2015","journal-title":"ATVB"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.omtn.2019.04.029","article-title":"Exosomes from Microglia Attenuate Photoreceptor Injury and Neovascularization in an Animal Model of Retinopathy of Prematurity","volume":"16","author":"Xu","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.32604\/biocell.2023.044177","article-title":"Inhibition of VEGF-A Expression in Hypoxia-Exposed Fetal Retinal Microvascular Endothelial Cells by Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells","volume":"47","author":"Li","year":"2023","journal-title":"Biocell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"11720","DOI":"10.1021\/acsnano.2c02531","article-title":"Discovering the Secret of Diseases by Incorporated Tear Exosomes Analysis via Rapid-Isolation System: iTEARS","volume":"16","author":"Hu","year":"2022","journal-title":"ACS Nano"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5301\/ejo.5000166","article-title":"Intravitreal Pegaptanib Combined with Diode Laser Therapy for Stage 3+ Retinopathy of Prematurity in Zone I and Posterior Zone II","volume":"22","author":"Autrata","year":"2012","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Modrzejewska, M., and Nazwalska, M. (2023). The Long-Term Observation of the Beneficial Effects of Treatment: 0.12 Mg Anti-VEGF Monotherapy or Anti-VEGF Combined Therapy and Diode-Laser in Various Stages of Retinopathy of Prematurity\u2014Series of Cases. JCM, 12.","DOI":"10.3390\/jcm12175644"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/10\/1377\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:14:16Z","timestamp":1760112856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/10\/1377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":62,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["ph17101377"],"URL":"https:\/\/doi.org\/10.3390\/ph17101377","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]}}}